Trial reportAntimicrobial agents and chemotherapy2020
Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.
Trial report in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02684240 (A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- How Can Pharmacology Help Us Overcome the Challenges of Drug Repositioning as Antivirals to Treat Emerging Pathogens? The Example of Covid-19.Clinical and translational science · 2026Review
- Prospects of Inhalable Formulations of Conventionally Administered Repurposed Drugs for Adjunctive Treatment of Drug-Resistant Tuberculosis: Supporting Evidence from Clinical Trials and Cohort Studies.Journal of aerosol medicine and pulmonary drug delivery · 2025Review
- Host-directed therapy for tuberculosis.European journal of medical research · 2025Review
- PROLONG: penalized regression for outcome guided longitudinal omics analysis with network and group constraints.Bioinformatics (Oxford, England) · 2025Article
- High variance in quantification ofAntimicrobial agents and chemotherapy · 2024Article
- The clinical antiprotozoal drug nitazoxanide and its metabolite tizoxanide extendActa pharmaceutica Sinica. B · 2024Article
- Commensal antimicrobial resistance mediates microbiome resilience to antibiotic disruption.Science translational medicine · 2024Article
- Adverse effect signature extraction and prediction for drugs treating COVID-19.Frontiers in genetics · 2022Article
- Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.Microorganisms · 2021Review
- Article
- Host-directed therapy to combat mycobacterial infections.Immunological reviews · 2021Review
- Gastrointestinal microbiota composition predicts peripheral inflammatory state during treatment of human tuberculosis.Nature communications · 2021Article
- Protein Kinase R in Bacterial Infections: Friend or Foe?Frontiers in immunology · 2021Review
- Progress in Redirecting Antiparasitic Drugs for Cancer Treatment.Drug design, development and therapy · 2021Review
- Urinary biomarkers of mycobacterial load and treatment response in pulmonary tuberculosis.JCI insight · 2020Article
- Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.Journal of virus eradication · 2020Article
- Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action inFrontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
Abstract
This study was conducted in treatment-naive adults with drug-susceptible pulmonary tuberculosis in Port-au-Prince, Haiti, to assess the safety, bactericidal activity, and pharmacokinetics of nitazoxanide (NTZ). This was a prospective phase II clinical trial in 30 adults with pulmonary tuberculosis. Twenty participants received 1 g of NTZ orally twice daily for 14 days. A control group of 10 participants received standard therapy over 14 days. The primary outcome was the change in time to culture positivity (TTP) in an automated liquid culture system. The most common adverse events seen in the NTZ group were gastrointestinal complaints and headache. The mean change in TTP in sputum over 14 days in the NTZ group was 3.2 h ± 22.6 h and was not statistically significant (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.